questionsmedicales.fr
Tumeurs
Tumeurs par type histologique
Leucémies
Leucémies : Questions médicales fréquentes
Termes MeSH sélectionnés :
Prostate-Specific Antigen
Diagnostic
5
Leucémie
Biopsie
Analyse sanguine
Hémogramme
Cytométrie en flux
Tests génétiques
Globules blancs
Anémie
Plaquettes
Radiographie
IRM
Extension de la maladie
Biopsie médullaire
Cellules leucémiques
Moelle osseuse
Symptômes
5
Fatigue
Fièvre
Infections
Perte de poids
Symptômes
Leucémie
Système immunitaire
Infections
Leucémie
Douleurs osseuses
Cellules leucémiques
Leucémie
Sueurs nocturnes
Symptômes
Leucémie
Prévention
5
Prévention
Facteurs de risque
Leucémie
Facteurs de risque
Radiations
Maladies génétiques
Tabagisme
Risque
Leucémie
Infections virales
Virus d'Epstein-Barr
Leucémie
Alimentation
Prévention
Santé générale
Traitements
5
Chimiothérapie
Radiothérapie
Greffe de moelle osseuse
Chimiothérapie
Types de leucémie
Efficacité
Greffe de moelle osseuse
Cellules souches
Traitement
Effets secondaires
Chimiothérapie
Nausées
Radiothérapie
Traitement
Complications
Complications
5
Complications
Infections
Saignements
Coagulation sanguine
Saignements
Leucémie
Problèmes cardiaques
Traitements
Leucémie
Infections
Système immunitaire
Leucémie
Douleurs chroniques
Traitements
Leucémie
Facteurs de risque
5
Facteurs de risque
Radiations
Antécédents familiaux
Troubles génétiques
Syndrome de Down
Risque
Antécédents
Chimiothérapie
Risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Leucémies : Questions médicales les plus fréquentes",
"headline": "Leucémies : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Leucémies : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-29",
"dateModified": "2025-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Leucémies"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs par type histologique",
"url": "https://questionsmedicales.fr/mesh/D009370",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs par type histologique",
"code": {
"@type": "MedicalCode",
"code": "D009370",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie myéloïde",
"alternateName": "Leukemia, Myeloid",
"url": "https://questionsmedicales.fr/mesh/D007951",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie myéloïde",
"code": {
"@type": "MedicalCode",
"code": "D007951",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe myéloïde",
"alternateName": "Leukemia, Myeloid, Acute",
"url": "https://questionsmedicales.fr/mesh/D015470",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe myéloïde",
"code": {
"@type": "MedicalCode",
"code": "D015470",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë à basophiles",
"alternateName": "Leukemia, Basophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015471",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë à basophiles",
"code": {
"@type": "MedicalCode",
"code": "D015471",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.125"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe à éosinophiles",
"alternateName": "Leukemia, Eosinophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015472",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe à éosinophiles",
"code": {
"@type": "MedicalCode",
"code": "D015472",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe mégacaryoblastique",
"alternateName": "Leukemia, Megakaryoblastic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007947",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe mégacaryoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007947",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe monoblastique",
"alternateName": "Leukemia, Monocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007948",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe monoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007948",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.484"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë promyélocytaire",
"alternateName": "Leukemia, Promyelocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015473",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë promyélocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015473",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.700"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë à basophiles",
"alternateName": "Leukemia, Basophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015471",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë à basophiles",
"code": {
"@type": "MedicalCode",
"code": "D015471",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.125"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe à éosinophiles",
"alternateName": "Leukemia, Eosinophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015472",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe à éosinophiles",
"code": {
"@type": "MedicalCode",
"code": "D015472",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe mégacaryoblastique",
"alternateName": "Leukemia, Megakaryoblastic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007947",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe mégacaryoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007947",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe monoblastique",
"alternateName": "Leukemia, Monocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007948",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe monoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007948",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.484"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë promyélocytaire",
"alternateName": "Leukemia, Promyelocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015473",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë promyélocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015473",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.700"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe myélomonocytaire",
"alternateName": "Leukemia, Myelomonocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015479",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe myélomonocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015479",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.520"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Leucémies",
"alternateName": "Leukemia",
"code": {
"@type": "MedicalCode",
"code": "D007938",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Kumaran Mudaliar",
"url": "https://questionsmedicales.fr/author/Kumaran%20Mudaliar",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology and Laboratory Medicine Loyola University Medical Center Maywood Illinois USA."
}
},
{
"@type": "Person",
"name": "Gregor Eisenwort",
"url": "https://questionsmedicales.fr/author/Gregor%20Eisenwort",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Irina Sadovnik",
"url": "https://questionsmedicales.fr/author/Irina%20Sadovnik",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Alexandra Keller",
"url": "https://questionsmedicales.fr/author/Alexandra%20Keller",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Daniela Berger",
"url": "https://questionsmedicales.fr/author/Daniela%20Berger",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Impact of Receipt of Information on Prostate-Specific Antigen Testing on Screening with the Prostate-Specific Antigen Test.",
"datePublished": "2023-01-18",
"url": "https://questionsmedicales.fr/article/36652189",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s13187-023-02264-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostate-Specific Antigen Screening in Transgender Patients.",
"datePublished": "2022-11-04",
"url": "https://questionsmedicales.fr/article/36344317",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.eururo.2022.09.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.",
"datePublished": "2022-07-21",
"url": "https://questionsmedicales.fr/article/35860909",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/pros.24414"
}
},
{
"@type": "ScholarlyArticle",
"name": "Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.",
"datePublished": "2022-09-24",
"url": "https://questionsmedicales.fr/article/36253300",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clgc.2022.09.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Opportunities for prostate-specific membrane antigen hybrid imaging in prostate cancer].",
"datePublished": "2023-09-13",
"url": "https://questionsmedicales.fr/article/37702749",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00120-023-02189-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://questionsmedicales.fr/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Leucémies",
"item": "https://questionsmedicales.fr/mesh/D007938"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Leucémies - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Leucémies",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Leucémies",
"description": "Comment diagnostique-t-on une leucémie ?\nQuels tests sont utilisés pour confirmer une leucémie ?\nQuels signes indiquent une leucémie lors des tests ?\nLes examens d'imagerie sont-ils nécessaires ?\nQuelle est l'importance de la biopsie médullaire ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Prostate-Specific+Antigen#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Leucémies",
"description": "Quels sont les symptômes courants de la leucémie ?\nLa perte de poids est-elle un symptôme de leucémie ?\nComment la leucémie affecte-t-elle le système immunitaire ?\nLes douleurs osseuses sont-elles liées à la leucémie ?\nLes sueurs nocturnes sont-elles un symptôme ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Prostate-Specific+Antigen#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Leucémies",
"description": "Peut-on prévenir la leucémie ?\nQuels facteurs de risque sont associés à la leucémie ?\nLe tabagisme augmente-t-il le risque de leucémie ?\nLes infections virales peuvent-elles causer la leucémie ?\nL'alimentation joue-t-elle un rôle dans la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Prostate-Specific+Antigen#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Leucémies",
"description": "Quels sont les traitements principaux de la leucémie ?\nLa chimiothérapie est-elle efficace contre toutes les leucémies ?\nQu'est-ce qu'une greffe de moelle osseuse ?\nQuels sont les effets secondaires de la chimiothérapie ?\nLa radiothérapie est-elle utilisée pour traiter la leucémie ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Prostate-Specific+Antigen#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Leucémies",
"description": "Quelles sont les complications possibles de la leucémie ?\nComment la leucémie affecte-t-elle la coagulation sanguine ?\nLes leucémies peuvent-elles entraîner des problèmes cardiaques ?\nQuelles infections sont fréquentes chez les patients leucémiques ?\nLes leucémies peuvent-elles causer des douleurs chroniques ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Prostate-Specific+Antigen#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Leucémies",
"description": "Quels sont les principaux facteurs de risque de leucémie ?\nL'âge influence-t-il le risque de leucémie ?\nLes troubles génétiques augmentent-ils le risque ?\nLe sexe joue-t-il un rôle dans le risque de leucémie ?\nLes antécédents de chimiothérapie augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Prostate-Specific+Antigen#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on une leucémie ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des analyses sanguines, une biopsie de moelle osseuse et des examens d'imagerie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer une leucémie ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'hémogramme, la cytométrie en flux et les tests génétiques."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une leucémie lors des tests ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une augmentation des globules blancs, une anémie et des plaquettes basses peuvent indiquer une leucémie."
}
},
{
"@type": "Question",
"name": "Les examens d'imagerie sont-ils nécessaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens comme la radiographie ou l'IRM peuvent aider à évaluer l'extension de la maladie."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la biopsie médullaire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie médullaire permet d'évaluer la présence de cellules leucémiques dans la moelle osseuse."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de la leucémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, fièvre, infections fréquentes et saignements faciles."
}
},
{
"@type": "Question",
"name": "La perte de poids est-elle un symptôme de leucémie ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une perte de poids inexpliquée peut être un symptôme de leucémie."
}
},
{
"@type": "Question",
"name": "Comment la leucémie affecte-t-elle le système immunitaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La leucémie affaiblit le système immunitaire, rendant le corps plus vulnérable aux infections."
}
},
{
"@type": "Question",
"name": "Les douleurs osseuses sont-elles liées à la leucémie ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs osseuses peuvent survenir en raison de l'accumulation de cellules leucémiques."
}
},
{
"@type": "Question",
"name": "Les sueurs nocturnes sont-elles un symptôme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les sueurs nocturnes peuvent être un symptôme courant chez les patients leucémiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la leucémie ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention garantie, mais éviter les facteurs de risque peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés à la leucémie ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition aux radiations, certains produits chimiques et des maladies génétiques."
}
},
{
"@type": "Question",
"name": "Le tabagisme augmente-t-il le risque de leucémie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour certains types de leucémie."
}
},
{
"@type": "Question",
"name": "Les infections virales peuvent-elles causer la leucémie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le virus d'Epstein-Barr, sont liées à un risque accru de leucémie."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut contribuer à la santé générale, mais ne prévient pas spécifiquement la leucémie."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements principaux de la leucémie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chimiothérapie, la radiothérapie et la greffe de moelle osseuse."
}
},
{
"@type": "Question",
"name": "La chimiothérapie est-elle efficace contre toutes les leucémies ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie est efficace pour de nombreux types de leucémie, mais pas tous."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une greffe de moelle osseuse ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est un traitement qui remplace la moelle osseuse malade par des cellules souches saines."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires de la chimiothérapie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, fatigue, perte de cheveux et infections."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle utilisée pour traiter la leucémie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être utilisée pour traiter certaines leucémies, surtout en cas de complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la leucémie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent infections graves, saignements, et complications liées aux traitements."
}
},
{
"@type": "Question",
"name": "Comment la leucémie affecte-t-elle la coagulation sanguine ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La leucémie peut entraîner des troubles de la coagulation, augmentant le risque de saignements."
}
},
{
"@type": "Question",
"name": "Les leucémies peuvent-elles entraîner des problèmes cardiaques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements de la leucémie peuvent augmenter le risque de problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Quelles infections sont fréquentes chez les patients leucémiques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les infections bactériennes et fongiques sont courantes en raison d'un système immunitaire affaibli."
}
},
{
"@type": "Question",
"name": "Les leucémies peuvent-elles causer des douleurs chroniques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les douleurs chroniques peuvent survenir en raison de la maladie ou des traitements."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque de leucémie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent l'exposition aux radiations, certains produits chimiques et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de leucémie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de leucémie augmente avec l'âge, surtout après 60 ans."
}
},
{
"@type": "Question",
"name": "Les troubles génétiques augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles comme le syndrome de Down augmentent le risque de leucémie."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque de leucémie ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les hommes ont généralement un risque plus élevé de leucémie que les femmes."
}
},
{
"@type": "Question",
"name": "Les antécédents de chimiothérapie augmentent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir reçu une chimiothérapie pour un autre cancer peut augmenter le risque de leucémie."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
└─
Leucémie myéloïde
Leukemia, Myeloid
D007951 -
C04.557.337.539
└─└─
Leucémie aigüe myéloïde
Leukemia, Myeloid, Acute
D015470 -
C04.557.337.539.275
└─└─
Leucémie aigüe myélomonocytaire
Leukemia, Myelomonocytic, Acute
D015479 -
C04.557.337.539.520
└─└─└─
Leucémie aiguë à basophiles
Leukemia, Basophilic, Acute
D015471 -
C04.557.337.539.275.125
└─└─└─
Leucémie aigüe à éosinophiles
Leukemia, Eosinophilic, Acute
D015472 -
C04.557.337.539.275.300
└─└─└─
Leucémie aigüe mégacaryoblastique
Leukemia, Megakaryoblastic, Acute
D007947 -
C04.557.337.539.275.450
└─└─└─
Leucémie aigüe monoblastique
Leukemia, Monocytic, Acute
D007948 -
C04.557.337.539.275.484
└─└─└─
Leucémie aiguë promyélocytaire
Leukemia, Promyelocytic, Acute
D015473 -
C04.557.337.539.275.700
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
1 publication dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
1 publication dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
There is controversy on prostate cancer screening with the prostate-specific antigen (PSA) test in the USA, and as a result, there has been an increased push for physicians to have a thorough discussi...
Approximately 0.4-1.3% of the worldwide population is transgender. Although the exact prevalence is unknown, there is an increase in open identification as transgender. Among transgender women (TW), t...
To assess our current understanding of CaP incidence and prostate-specific antigen (PSA) screening in TW....
We performed a nonsystematic narrative review of all PubMed publications through June 2022 according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. Given ...
There is no consensus regarding PSA screening in TW from any of the major societies, and TW are largely absent from guidelines. Case report data suggest that TW with CaP may have more aggressive disea...
We are in the infancy of our understanding of PSA screening in TW. Important avenues for future research include understanding the risks/benefits of PSA screening in TW, how best to mitigate potential...
We examined patterns of prostate cancer screening for transgender women. Little is known about prostate cancer incidence or screening in this population. Additional research is needed to establish gui...
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is increasingly incorporated in the therapeutic algorithm of patients with metastatic castration-resistant prostate cancer ...
In this bicentric analysis, we included 184 mCRPC patients treated with...
A total of 114/184 patients (62.0%) showed any PSA decline (PSA response >50%, 55/184 [29.9%]). For individuals exhibiting a PSA decline >50%, OS of 19 months was significantly longer relative to nonr...
In mCRPC patients scheduled for RLT, early biochemical response was tightly linked to prolonged survival, irrespective of the magnitude of PSA decline. As such, even in patients with PSA decrease of l...
In this study, it was aimed to investigate the reliability of total prostate-specific antigen (t-PSA) in prostate cancer screening in hyperglycemic (≥126 mg/dL) individuals....
This research was planned as a cross-sectional retrospective study. Three hundred eleven cases which underwent biopsy with the suspicion of prostate cancer in the hospital were included in the study. ...
It was determined that the t-PSA measurement was higher in the patient group with cancer (P < .001). It was determined that the median t-PSA levels of the intermediate and high cancer groups were high...
As a contribution to literature, we found that the t-PSA test lost its sensitivity in cases with plasma glucose levels above normal. Loss of sensitivity may result in underdiagnosis in prostate cancer...
Prostate-specific membrane antigen (PSMA) hybrid imaging is a promising new technique gaining importance in the field of prostate cancer (PCa) diagnosis and treatment planning. By combining PSMA radio...
Prostate-specific antigen (PSA) screening for prostate cancer is controversial but may be associated with benefit for certain high-risk groups....
To evaluate associations of county-level PSA screening prevalence with prostate cancer outcomes, as well as variation by sociodemographic and clinical factors....
This cohort study used data from cancer registries based in 8 US states on Hispanic, non-Hispanic Black, and non-Hispanic White men aged 40 to 99 years who received a diagnosis of prostate cancer betw...
County-level PSA screening prevalence was estimated using the Behavior Risk Factor Surveillance System survey data from 2004, 2006, 2008, 2010, and 2012 and weighted by population characteristics....
Multivariable logistic, Cox proportional hazards regression, and competing risks models were fit to estimate adjusted odds ratios (AOR) and adjusted hazard ratios (AHR) for associations of county-leve...
Of 814 987 men with prostate cancer, the mean (SD) age was 67.3 (9.8) years, 7.8% were Hispanic, 12.2% were non-Hispanic Black, and 80.0% were non-Hispanic White; 17.0% had advanced disease. There wer...
This population-based cohort study of men with prostate cancer suggests that higher county-level prevalence of PSA screening was associated with lower odds of advanced disease, all-cause mortality, an...
The incidence rate of prostate cancer (PCa) has continued to rise in Korea. This study aimed to construct and evaluate a 5-year PCa risk prediction model using a cohort with PSA < 10 ng/mL by incorpor...
The PCa risk prediction model including PSA levels and individual risk factors was constructed using a cohort of 69,319 participants from the Kangbuk Samsung Health Study. 201 registered PCa incidence...
The risk prediction model included age, smoking status, alcohol consumption, family history of PCa, past medical history of dyslipidemia, cholesterol levels, and PSA level. Especially, an elevated PSA...
Our risk prediction model was effective in predicting PCa in a population according to PSA levels. When PSA levels are inconclusive, an assessment of both PSA and specific individual risk factors (e.g...
For metastatic hormone naïve prostate cancer patients, androgen deprivation therapy (ADT) with escalation therapy including docetaxel and/or androgen targeting drugs is the standard therapy. However, ...
Prostate biopsies from 92 patients with metastatic hormone naïve PC (PSA > 80 ng/mL or clinical metastases) were immunohistochemically evaluated for PSA and Ki67. Gene expression analysis was performe...
The immunohistochemical score for PSA was the strongest prognostic factor for progression-free and overall survival after ADT. Consequently, the ratio between Ki67 and PSA displayed a stronger prognos...
PSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The re...
To investigate the value of serum free prostate-specific antigen density (fPSAD) in the diagnosis of prostate cancer (PCa)....
The data of 558 patients who underwent transrectal ultrasound-guided prostate biopsy were retrospectively analyzed. According to the pathological results, the patients were divided into a PCa group an...
tPSA, PSAD, (f/t)/PSAD, and fPSAD had high accuracy in predicting PCa with AUC values of 0.820, 0.900, 0.846, and 0.867. fPSAD showed lower diagnostic sensitivity but significantly higher specificity ...
With the optimal cutoff value of 0.062, fPSAD has a higher diagnostic value for PCa than tPSA, f/tPSA, (f/t)/PSAD, and PSAD, and can well predict the risk of PCa, significantly improve the clinical di...
Benign prostatic hyperplasia (BPH) is the most common cause of bladder outlet obstruction in men over the age of 50 years. An association between the prostate specific antigen (PSA), International Pro...
To determine the correlation between the PSA, IPSS and PV in men of African descent....
This was a cross sectional analysis involving 92 patients diagnosed as having symptomatic BPH at the Ho Teaching Hospital....
The data were collected using standardised questionnaires. The IPSS determined urinary symptom severity. The PV was determined using a transabdominal ultrasound machine. Serum PSA was retrieved from t...
The mean PV was 61.04 cm3 ± 21.95 cm3, the mean PSA was 4.21 ng/mL ± 3.85 ng/mL, and mean IPSS of 21.59 ± 3.78. The Pearson's correlation between PV and PSA was 0.283 (p = 0.01), between PV and IPSS w...
This study showed that serum PSA has a positive correlation with PV. However, IPSS had no significant association with PSA or PV in patients with BPH.Contribution: This study provides insights into th...
